What's New for 2015?

 

The change of location isn't the only thing that's new. We now also have Keynote Interviews, Revolutionary Topics and New People from a wide range of companies. All this is to ensure World CDx Berlin 2015 is the best one yet.

Download the brochure for the full agenda and speaker line-up.

Forging the Path to Precision Medicine

The time to invest in companion diagnostics is now and World CDx Berlin 2015 has brought together the leaders who continue to define this central pillar of true personalised healthcare.

With partnerships being signed at an unprecedented rate and the field rapidly coming of age scientifically, World CDx will once again guide drug, diagnostic and technology developers all the way from initial target identification to market launch of Rx-Dx combinations.

World CDx Berlin 2015 will enable you to:

  1. Successfully align drug-companion diagnostic co-development via lessons learnt from marketed combinations and current leading clinical trials showcased by Pfizer, Roche and  GSK
  2. Understand key factors for commercialisation and successfully navigate a rapidly changing and uncertain regulatory and reimbursement landscape with EMA, NICE and industry perspectives
  3. Understand how to maximise the potential of NGS-based CDx development with exclusive insight from ThermoFisher Scientific, Novartis, Illumina and Boehringer Ingelheim
  4. Construct a robust biomarker strategy all the way from initial identification through to clinical validation by harnessing industry-leading expertise from Bayer, Teva and Radbound Medical Center
  5. Effectively partner at the correct time to yield commercial CDx success with case studies from Sanofi, NanoString Technologies and Arno Therapeutics
  6. Harness the burgeoning application of circulating and cell-free biomarkers in companion diagnostic development with expert knowledge from AstraZeneca, University of Dusseldorf and MerckSerono

Featured Speakers

  • Khusru AsadullahVice President, Head of Global Biomarkers Bayer

  • Richard BullerVice President, Oncology Clinical Development Pfizer

  • Maria OrrExecutive Director, Personalised Healthcare & Biomarkers AstraZeneca

  • Dan RhodesHead of Oncology Strategy Thermo Fisher Scientific